Clinical Trial Update: An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a fixed-dose rosiglitazone/glimepiride combination for Type 2 diabetes in Chinese patients was terminated; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glimepiride (glimepiride)
• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: TERMINATED | Results posted: 2012-01-13